ID   HT1080/DR4
AC   CVCL_6C48
DR   cancercelllines; CVCL_6C48
DR   Wikidata; Q54896569
RX   PubMed=1673331;
RX   PubMed=1976136;
RX   PubMed=2896069;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269.
DI   NCIt; C3043; Fibrosarcoma
DI   ORDO; Orphanet_2030; Fibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0317 ! HT-1080
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 23-02-16; Last updated: 05-10-23; Version: 15
//
RX   PubMed=1673331;
RA   Slovak M.L., Coccia M., Meltzer P.S., Trent J.M.;
RT   "Molecular analysis of two human doxorubicin-resistant cell lines:
RT   evidence for differing multidrug resistance mechanisms.";
RL   Anticancer Res. 11:423-428(1991).
//
RX   PubMed=1976136; DOI=10.1093/jnci/82.19.1553;
RA   Zwelling L.A., Slovak M.L., Doroshow J.H., Hinds M., Chan D.,
RA   Parker E., Mayes J., Sie K.L., Meltzer P.S., Trent J.M.;
RT   "HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line
RT   exhibiting resistance to topoisomerase II-reactive drugs despite the
RT   presence of a drug-sensitive topoisomerase II.";
RL   J. Natl. Cancer Inst. 82:1553-1561(1990).
//
RX   PubMed=2896069;
RA   Slovak M.L., Hoeltge G.A., Dalton W.S., Trent J.M.;
RT   "Pharmacological and biological evidence for differing mechanisms of
RT   doxorubicin resistance in two human tumor cell lines.";
RL   Cancer Res. 48:2793-2797(1988).
//